Answers are grounded in this paper and cite their sources.
Gefitinib is inactive as a single agent in patients with previously treated colorectal cancer. In tumor samples, gefitinib did not inhibit activation of its proximal target, EGFR. Trends were observed for inhibition of downstream regulators of cellular survival and proliferation in patients achieving longer progression-free survival.
No takes yet. Share an insight, caveat, or question.
Rothenberg et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: